Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Rb1 loss modifies but does not initiate alveolar rhabdomyosarcoma.
Kikuchi K, Taniguchi E, Chen HH, Svalina MN, Abraham J, Huang ET, Nishijo K, Davis S, Louden C, Zarzabal LA, Recht O, Bajwa A, Berlow N, Suelves M, Perkins SL, Meltzer PS, Mansoor A, Michalek JE, Chen Y, Rubin BP, Keller C. Kikuchi K, et al. Among authors: keller c. Skelet Muscle. 2013 Nov 25;3(1):27. doi: 10.1186/2044-5040-3-27. Skelet Muscle. 2013. PMID: 24274149 Free PMC article.
YAPping about differentiation therapy in muscle cancer.
Svalina MN, Keller C. Svalina MN, et al. Among authors: keller c. Cancer Cell. 2014 Aug 11;26(2):154-5. doi: 10.1016/j.ccr.2014.07.011. Cancer Cell. 2014. PMID: 25117705 Free PMC article.
Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.
Noujaim J, Thway K, Bajwa Z, Bajwa A, Maki RG, Jones RL, Keller C. Noujaim J, et al. Among authors: keller c. Front Oncol. 2015 Aug 17;5:186. doi: 10.3389/fonc.2015.00186. eCollection 2015. Front Oncol. 2015. PMID: 26347853 Free PMC article. Review.
IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.
Svalina MN, Kikuchi K, Abraham J, Lal S, Davare MA, Settelmeyer TP, Young MC, Peckham JL, Cho YJ, Michalek JE, Hernandez BS, Berlow NE, Jackson M, Guillaume DJ, Selden NR, Bigner DD, Nazemi KJ, Green SC, Corless CL, Gultekin S, Mansoor A, Rubin BP, Woltjer R, Keller C. Svalina MN, et al. Among authors: keller c. Sci Rep. 2016 Jun 3;6:27012. doi: 10.1038/srep27012. Sci Rep. 2016. PMID: 27255663 Free PMC article.
EphB4/EphrinB2 therapeutics in Rhabdomyosarcoma.
Randolph ME, Cleary MM, Bajwa Z, Svalina MN, Young MC, Mansoor A, Kaur P, Bult CJ, Goros MW, Michalek JE, Xiang S, Keck J, Krasnoperov V, Gill P, Keller C. Randolph ME, et al. Among authors: keller c. PLoS One. 2017 Aug 17;12(8):e0183161. doi: 10.1371/journal.pone.0183161. eCollection 2017. PLoS One. 2017. PMID: 28817624 Free PMC article.
NFκB signaling in alveolar rhabdomyosarcoma.
Cleary MM, Mansoor A, Settelmeyer T, Ijiri Y, Ladner KJ, Svalina MN, Rubin BP, Guttridge DC, Keller C. Cleary MM, et al. Among authors: keller c. Dis Model Mech. 2017 Sep 1;10(9):1109-1115. doi: 10.1242/dmm.030882. Dis Model Mech. 2017. PMID: 28883017 Free PMC article.
Murine model of hepatic breast cancer.
Rikhi R, Wilson EM, Deas O, Svalina MN, Bial J, Mansoor A, Cairo S, Keller C. Rikhi R, et al. Among authors: keller c. Biochem Biophys Rep. 2016 Aug 4;8:1-5. doi: 10.1016/j.bbrep.2016.07.021. eCollection 2016 Dec. Biochem Biophys Rep. 2016. PMID: 28955934 Free PMC article.
Preclinical testing of the glycogen synthase kinase-3β inhibitor tideglusib for rhabdomyosarcoma.
Bharathy N, Svalina MN, Settelmeyer TP, Cleary MM, Berlow NE, Airhart SD, Xiang S, Keck J, Hayden JB, Shern JF, Mansoor A, Lathara M, Srinivasa G, Langenau DM, Keller C. Bharathy N, et al. Among authors: keller c. Oncotarget. 2017 Jun 16;8(38):62976-62983. doi: 10.18632/oncotarget.18520. eCollection 2017 Sep 8. Oncotarget. 2017. PMID: 28968964 Free PMC article.
1,872 results